Seattle Genetics, known as Seagen, has announced positive results from its Phase II trial for early-stage classical Hodgkin lymphoma. The company reported that Adcetris, in combination with Bristol Myers Squibb’s PD-1 inhibitor and standard chemotherapy agents, led to complete remission in 93% of patients. In Part C of the three-part study, which involved 150 patients, Adcetris showed a 98% overall response rate at the end of treatment. The goal of ongoing Adcetris studies is to “develop curative treatments that improve survival while also reducing toxicity”. Pfizer is set to acquire Seagen and its top-selling drug Adcetris.
Keywords: Seagen, Adcetris, classical Hodgkin lymphoma, Bristol Myers Squibb’s PD-1 inhibitor, chemotherapy.
Seagen's announcement marks a significant step forward in the development of curative treatments for early-stage classical Hodgkin lymphoma. The high complete remission rate seen in patients treated with Adcetris suggests that this drug could become an important part of future treatment regimens. However, BMS's Opdivo also demonstrated promising results in advanced untreated cHL but appeared to be safer than Adcetris. With Pfizer set to